These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Protein Kinase N1 control of androgen-responsive serum response factor action provides rationale for novel prostate cancer treatment strategy. Venkadakrishnan VB; DePriest AD; Kumari S; Senapati D; Ben-Salem S; Su Y; Mudduluru G; Hu Q; Cortes E; Pop E; Mohler JL; Azabdaftari G; Attwood K; Shah RB; Jamieson C; Dehm SM; Magi-Galluzzi C; Klein E; Sharifi N; Liu S; Heemers HV Oncogene; 2019 Jun; 38(23):4496-4511. PubMed ID: 30742064 [TBL] [Abstract][Full Text] [Related]
3. Identification of a RhoA- and SRF-dependent mechanism of androgen action that is associated with prostate cancer progression. Heemers HV Curr Drug Targets; 2013 Apr; 14(4):481-9. PubMed ID: 23469924 [TBL] [Abstract][Full Text] [Related]
4. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Schmidt LJ; Duncan K; Yadav N; Regan KM; Verone AR; Lohse CM; Pop EA; Attwood K; Wilding G; Mohler JL; Sebo TJ; Tindall DJ; Heemers HV Mol Endocrinol; 2012 May; 26(5):716-35. PubMed ID: 22456196 [TBL] [Abstract][Full Text] [Related]
5. Relationship between serum response factor and androgen receptor in prostate cancer. Prencipe M; O'Neill A; O'Hurley G; Nguyen LK; Fabre A; Bjartell A; Gallagher WM; Morrissey C; Kay EW; Watson RW Prostate; 2015 Nov; 75(15):1704-17. PubMed ID: 26250344 [TBL] [Abstract][Full Text] [Related]
6. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells. Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626 [TBL] [Abstract][Full Text] [Related]
7. PDCD4 Is an Androgen-Repressed Tumor Suppressor that Regulates Prostate Cancer Growth and Castration Resistance. Zennami K; Choi SM; Liao R; Li Y; Dinalankara W; Marchionni L; Rafiqi FH; Kurozumi A; Hatano K; Lupold SE Mol Cancer Res; 2019 Feb; 17(2):618-627. PubMed ID: 30518628 [TBL] [Abstract][Full Text] [Related]
8. Bone morphogenetic protein-6 induces castration resistance in prostate cancer cells through tumor infiltrating macrophages. Lee GT; Jung YS; Ha YS; Kim JH; Kim WJ; Kim IY Cancer Sci; 2013 Aug; 104(8):1027-32. PubMed ID: 23710822 [TBL] [Abstract][Full Text] [Related]
9. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer. Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301 [TBL] [Abstract][Full Text] [Related]
10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Shafi AA; Yen AE; Weigel NL Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952 [TBL] [Abstract][Full Text] [Related]
11. Angiogenin mediates androgen-stimulated prostate cancer growth and enables castration resistance. Li S; Hu MG; Sun Y; Yoshioka N; Ibaragi S; Sheng J; Sun G; Kishimoto K; Hu GF Mol Cancer Res; 2013 Oct; 11(10):1203-14. PubMed ID: 23851444 [TBL] [Abstract][Full Text] [Related]
12. Androgens induce a distinct response of epithelial-mesenchymal transition factors in human prostate cancer cells. Colditz J; Rupf B; Maiwald C; Baniahmad A Mol Cell Biochem; 2016 Oct; 421(1-2):139-47. PubMed ID: 27562825 [TBL] [Abstract][Full Text] [Related]
13. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer. Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511 [TBL] [Abstract][Full Text] [Related]
15. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy. Fiandalo MV; Wu W; Mohler JL Curr Drug Targets; 2013 Apr; 14(4):420-40. PubMed ID: 23565755 [TBL] [Abstract][Full Text] [Related]
16. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer. Heemers HV; Regan KM; Dehm SM; Tindall DJ Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004 [TBL] [Abstract][Full Text] [Related]
18. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer. Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513 [TBL] [Abstract][Full Text] [Related]
19. Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling. Wang T; Song W; Chen Y; Chen R; Liu Z; Wu L; Li M; Yang J; Wang L; Liu J; Ye Z; Wang C; Chen K Clin Cancer Res; 2016 Mar; 22(6):1531-44. PubMed ID: 26527749 [TBL] [Abstract][Full Text] [Related]
20. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo. Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]